MannKind Corporation to Lay Off 41 Pct of its Workforce After Drug Delays from FDA, Terminates Supply Deal

February 11, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LA Times -- Mannkind Corp., the Valencia biotech firm, announced that it would lay off 41% of its workforce and focus on receiving regulatory approval for its long-delayed insulin inhaler being developed for people with diabetes.

Twitter
LinkedIn
Facebook
Email
Print

Job creations

Food and Drug Administration (FDA)